Zaptuzumab

Zaptuzumab (AD5-10) is a DR5-specific humanized monoclonal antibody that selectively binds to DR5 with high affinity. Zaptuzumab specifically induces cancer cell death by both caspase-apoptosis and autophagic cell death (ACD) . Zaptuzumab activates both ADCC and CDC. Zaptuzumab induces ROS generation and GSH level reduction. Zaptuzumab shows a significant suppression of the tumor growth and good safety in various xenografts mice tumor models[1][2][3][4][5].

2378046-35-4

AD5-10

12352203

Akt; Apoptosis; Atg8/LC3; Beclin1; Caspase; JNK; TNF Receptor

Apoptosis; Autophagy; MAPK/ERK Pathway; PI3K/Akt/mTOR

Cancer-Kinase/protease

Cancer

[1]Zhang S, et al. A novel anti-DR5 antibody-drug conjugate possesses a high-potential therapeutic efficacy for leukemia and solid tumors. Theranostics. 2019 Jul 13;9 (18) :5412-5423. |[2]Zhang S, et al. Preclinical evaluation of a novel antibody-drug conjugate targeting DR5 for lymphoblastic leukemia therapy. Mol Ther Oncolytics. 2021 Apr 29;21:329-339.|[3]Chen L, et al. A novel humanized anti-tumor necrosis factor-related apoptosis-inducing ligand-R2 monoclonal antibody induces apoptotic and autophagic cell death. IUBMB Life. 2017 Sep;69 (9) :735-744.|[4]Tang W, et al. TRAIL receptor mediates inflammatory cytokine release in an NF-kappaB-dependent manner. Cell Res. 2009 Jun;19 (6) :758-67.|[5]Chen C, et al. An agonistic monoclonal antibody against DR5 induces ROS production, sustained JNK activation and Endo G release in Jurkat leukemia cells. Cell Res. 2009 Aug;19 (8) :984-95.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P991570/

Inhibitory Antibodies

No Development Reported